Ibeawuchi Okoroafor

ORCID: 0000-0002-4632-3206
Publications
Citations
Views
---
Saved
---
About
Contact & Profiles
Research Areas
  • Inflammatory Bowel Disease
  • Systemic Sclerosis and Related Diseases
  • Immunodeficiency and Autoimmune Disorders
  • Medication Adherence and Compliance
  • Mycobacterium research and diagnosis
  • Gut microbiota and health
  • Mental Health Treatment and Access
  • Bipolar Disorder and Treatment
  • Telemedicine and Telehealth Implementation
  • Single-cell and spatial transcriptomics
  • Chronic Lymphocytic Leukemia Research
  • HIV/AIDS Research and Interventions
  • Renal Diseases and Glomerulopathies
  • Vasculitis and related conditions
  • Chronic Kidney Disease and Diabetes
  • Celiac Disease Research and Management
  • T-cell and Retrovirus Studies
  • HIV-related health complications and treatments
  • HIV/AIDS drug development and treatment
  • Biological Research and Disease Studies
  • Biomedical and Engineering Education
  • Microscopic Colitis

Boston Children's Hospital
2023

Harvard University
2023

Icahn School of Medicine at Mount Sinai
2019-2021

University of Nigeria
2016

Immunosuppression in solid organ transplant recipients inhibits protective immune responsiveness to pathogens and vaccines. However, specific cell states that associate with failure generate immunity are not known. Here, we perform scRNAseq CyTOF analyses of PBMC from 12 pediatric 8 healthy children revealing the full spectrum present these individuals, examine association generation humoral cellular following vaccination. We determined clonal expansion a subset CD8+ effector T cells is...

10.1101/2025.03.25.25324615 preprint EN medRxiv (Cold Spring Harbor Laboratory) 2025-03-26

Patients with HIV have higher thrombogenicity that correlates markers of inflammation; both respond to clopidogrel treatment.

10.1126/sciadv.aav5463 article EN cc-by-nc Science Advances 2019-06-01

Abstract Background Very early onset inflammatory bowel disease (VEOIBD) is defined as in patients younger than 6 years. Challenges treatment of VEOIBD include lack approved therapies and increased incidence monogenic immunodeficiencies. We report on patterns anti-TNF use, efficacy, safety a large cohort with VEOIBD. Methods receiving care at single center were prospectively enrolled data registry biorepository starting 2012. Whole exome sequencing was available to all patients. Clinical...

10.1093/ibd/izad196 article EN Inflammatory Bowel Diseases 2023-10-17

Abstract BACKGROUND Very early onset inflammatory bowel disease (VEOIBD) is defined as prior to age 6. VEOIBD monogenic in >5% of cases; however, the remaining cases, molecular basis unknown. We aimed utilize bulk RNA-seq blood 1) define transcriptional signatures established IBD and 2) inform novel diagnoses. METHODS sequenced transcriptomes 115 whole samples, comprising patients with a known cause (n=35), without (n=70), healthy controls (n=10). focused on genes whose normalized...

10.1093/ibd/izac247.108 article EN Inflammatory Bowel Diseases 2023-01-26
Coming Soon ...